started · updated
Fragrance industry investigates impact of weight-loss drugs on scent preferences
Major fragrance corporations, including Givaudan, IFF, CPL Aromas, and L’Oréal, are investigating whether GLP-1 weight-loss medications influence consumer scent preferences. Researchers are examining if these drugs cause a shift in how individuals perceive odors, potentially making some scents more attractive or repulsive as a sensory substitute for reduced food enjoyment.
Market data indicates a significant rise in the popularity of 'gourmand' fragrances—scents that mimic edible notes. According to Mintel, gourmand scents accounted for 24 percent of new perfume products, up from nine percent two years ago. While manufacturers are experimenting with increasingly complex notes such as whisky, truffle, miso, and even Tabasco, a direct causal link between weight-loss injections and changing olfactory tastes remains unproven.
In the United States, data from NIQ suggests that individuals using GLP-1 medications spend 26 percent more on fragrances than the general population average, though it is unclear if this is driven by the medication's physiological effects or other lifestyle factors.
Entities
Eli Lilly · Givaudan · IFF · International Flavors & Fragrances · L’Oréal · Novo Nordisk
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] Fragrance manufacturers are experimenting with scents like whisky, truffle, miso, and Tabasco. www.bild.de
- [● 4 SOURCES] Gourmand and edible scents rose from 9% to 24% of new fragrance innovations over two years. www.merkur.de · www.tz.de · www.bild.de
- [● 3 SOURCES] IFF research suggests GLP-1 therapies may increase interest in scents as a source of sensory pleasure. www.merkur.de · www.tz.de
- [● 3 SOURCES] Givaudan observed that GLP-1 users experience changes in scent attraction and repulsion. www.merkur.de · www.tz.de
- [○ 1 SOURCE] GLP-1 medication users in the US spend 26% more on fragrances than the average person. www.bild.de